Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF), a biopharmaceutical company developing anti-infective drug candidates, today announced it has recruited Don Cilla, PharmD, MBA, to serve as the company’s new chief development officer (CDO), effective November 1, 2020.
A company producing high value industrial chemicals from sustainably harvested seaweed has won $40,000 and other support. The business, SeaChange Biochemistry, is one of seven Nova Scotia start-ups selected after a recent competitive call for submissions in the GreenShoots competition.
3D BioFibR Inc., an advanced biofibre materials company, announced today it has raised $550,000 to fund development and commercialization of its tissue engineering/biomedical device products and to scale up manufacturing of its novel biofibre-based platform.
Innovacorp received 60 submissions for its latest round of Sprint and, after many hours of reviewing and deliberating, selected nine companies to participate in the program. Congratulations to the start-ups chosen for Innovacorp’s 2020 Sprint fall intake.
Halifax-based start-up Rimot.io Inc. is testing a safer, more secure alternative to screen for COVID-19 with local innovation partners Halifax Partnership and Volta.
The company behind a portable analyzer to measure cannabis safety and quality has earned $50,000 and a spot in Innovacorp’s six-month Accelerate Program. The business, Greenlight Analytical, is one of five Nova Scotia start-ups selected after a recent competitive call for submissions.
CarbonCure Technologies, a Canadian clean technology company that develops carbon dioxide removal (CDR) solutions for the concrete industry, today announced an investment by leading technology and property developers.
DMF Medical Incorporated, a privately held medical device company focused on making anesthesia safer, is pleased to announce it has received a Class II medical device license from Health Canada to sell its memsorb™ carbon dioxide (CO2) filtration device in the Canadian market.
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) as of the opening of trading on Wednesday, September 16, 2020, under the Company's current trading symbol, "APLI."